LP-98 injections for adults with untreated HIV

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 forInjection in Antiretroviral Therapy-Naive HIV-Infected Individuals

This trial tries LP-98 injections at three doses in adults with HIV who have not started antiretroviral therapy to see if the drug is safe, lowers viral load, and how it behaves in the body.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Shanxi Kangbao Biological Product Co., Ltd. (Industry-sponsored)
• Locations: 1 site (Tianjin, Tianjin Municipality)
• Trial ID: NCT07433387 on ClinicalTrials.gov

What this trial studies

This multicenter, open-label sequential cohort study enrolls 30 ART-naive adults with HIV into three sequential dose cohorts (20 mg, 40 mg, 80 mg). Participants receive subcutaneous LP-98 every 14 days for four doses with safety, pharmacokinetic, and preliminary antiviral activity measured through treatment and follow-up visits. Cohorts enroll from low to high dose with 10 subjects per cohort and a screening, treatment (D1–D57), and follow-up (D58–D71) period for a total participation time of about 99 days. The primary goals are to characterize safety, tolerability, and PK while observing any early signs of viral load reduction.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18–65 who are ART-naive with plasma HIV RNA ≥1000 copies/mL, CD4 ≥200 cells/μL, meet the study's weight and non-reproductive female or contraception requirements, and can attend visits at the trial site.

Not a fit: People already on antiretroviral therapy, those with CD4 counts below 200 or HIV RNA under 1000 copies/mL, pregnant or reproductive females who do not meet the non-reproductive criteria, children, and those unable to travel to the study site are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, LP-98 could offer a short-course, subcutaneous treatment that reduces viral load with infrequent dosing and may provide an alternative to daily oral therapy.

How similar studies have performed: Long-acting injectable antiretroviral regimens such as cabotegravir/rilpivirine have shown clinical success, but LP-98 itself is a novel agent with limited prior human data.

Eligibility criteria

Inclusion Criteria:

1. The subject must voluntarily agree to participate in the study and provide informed consent before undergoing any study-related assessments.
2. At the time of screening, the subject must be between 18 and 65 years of age (inclusive), either male or female.
3. At the time of screening, male subjects must weigh at least 50 kg, and female subjects must weigh at least 45 kg.
4. Plasma HIV RNA levels must be ≥1000 copies/mL, and CD4+ T lymphocyte count must be ≥200 cells/μL.
5. For Female Subjects: Only non-reproductive females will be included, which includes those who have undergone surgical sterilization (documented hysterectomy or bilateral oophorectomy) at least 6 weeks prior to the screening visit, or those who have been postmenopausal for at least 12 months (confirmed by a follicle-stimulating hormone (FSH) level ≥40 IU/L).
6. For Male Subjects with Fertile Female Partners: The subject must agree to use a non-pharmacological contraception method for 14 days prior to dosing, during the study, and for 3 months following the administration of the study drug. Male subjects must not donate sperm during this period.
7. The subject must be willing to adhere to the study protocol, including visits, study treatment, laboratory tests, and other study-related procedures and requirements.

Exclusion Criteria:

1. Known allergy to the study drug or its excipients, or a history of severe allergic reactions (including any food allergies or drug allergies).
2. Has previously received antiviral therapy (ART) or has been vaccinated against HIV.
3. A history of severe disease or the presence of other severe chronic conditions.
4. A history of mental health disorders or a family history of psychiatric diseases.
5. Any of the Following Conditions:

1）Persistent unexplained fever above 38°C within 1 month prior to screening or during the screening phase.

2）Persistent diarrhea (more than 3 bowel movements per day) within 1 month prior to screening or during the screening phase.

3）Severe infections, opportunistic infections, or sepsis within 6 months prior to screening or during the screening phase.

6、Positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab).

7、Abnormal 12-lead electrocardiogram (ECG) findings with clinical significance at screening, such as a male QTcF interval (Fridericia correction formula) \> 450 ms, or female QTcF \> 470 ms.

8、Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 times the upper limit of normal (ULN), or total bilirubin \> 1.5 times ULN at screening.

9、Serum creatinine clearance (Ccr) \< 60 mL/min at screening (calculated using the Cockcroft-Gault formula).

10、Known or suspected history of drug abuse (including morphine, methamphetamine, ketamine, dimethylthioamphetamine, tetrahydrocannabinolic acid, cocaine), or a positive baseline drug screening test.

11、A history of alcohol abuse within the past year (defined as consuming more than 14 standard units of alcohol per week, where 1 standard unit is 14 g of alcohol, equivalent to 360 mL of 5% beer, 45 mL of 40% liquor, or 120 mL of 12% wine), or inability to comply with the study's alcohol prohibition during the study.

12、Smoking more than 5 cigarettes per day within the last 3 months prior to screening, or inability to comply with the study's smoking prohibition during the study.

13、Receiving any vaccine within 3 months prior to screening, or planning to receive any vaccine during the study.

14、Received any investigational drug treatment or participated in any drug/device trial (excluding in vitro diagnostic devices) within 3 months prior to dosing.

15、Major surgery within 30 days prior to dosing, or planned major surgery during the study.

16、Blood donation or loss of ≥ 400 mL within 3 months prior to screening, or receiving a blood transfusion during this period.

17、Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.

Where this trial is running

Tianjin, Tianjin Municipality

• Tianjin Second People's Hospital — Tianjin, Tianjin Municipality, China (Recruiting)

Study contacts

• Principal investigator: Ping Ma, Doctor — Tianjin Second People's Hospital
• Study coordinator: Yuxian He, Doctor

Conditions HIV; LP-98